Loading…
Loading…
Not all low blood counts are benign — and not all MDS needs immediate treatment
Myelodysplastic syndromes (MDS) are clonal marrow disorders characterised by ineffective haematopoiesis, cytopenias and dysplasia, with a variable risk of progression to acute myeloid leukemia. Diagnosis integrates blood counts, marrow morphology, cytogenetics and molecular findings. Treatment is risk-adapted and ranges from observation and supportive care to hypomethylating agents and transplant.
Haematology & Haemato-Oncology
Authored and reviewed by Dr. Sachita Baniya (MBBS, FCPS (Clinical Haematology), NMC 20158). Evidence-based, no fabricated outcomes.
Myelodysplastic syndromes (MDS) are clonal marrow disorders characterised by ineffective haematopoiesis, cytopenias and dysplasia, with a variable risk of progression to acute myeloid leukemia. Diagnosis integrates blood counts, marrow morphology, cytogenetics and molecular findings. Treatment is risk-adapted and ranges from observation and supportive care to hypomethylating agents and transplant.
Reviewed by Dr. Sachita Baniya, MBBS, FCPS — Consultant Haemato-Oncologist & Clinical Hematologist (NMC 20158). For evaluation, contact the respective hospital or cancer centre — Kathmandu Cancer Center (KCC) Nepal, Civil Service Hospital Kathmandu, or Advanced Care Hospital.
MDS is suspected when persistent cytopenias are accompanied by dysplastic marrow features. Bone marrow aspiration and biopsy, iron staining, flow cytometry, cytogenetics and molecular testing establish the diagnosis and exclude mimics. The IPSS-R and molecular scores estimate prognosis and guide treatment intensity.
Lower-risk disease may be managed with observation, growth factors, transfusion support and lenalidomide in selected del(5q) cases. Higher-risk disease may be treated with hypomethylating agents and considered for allogeneic transplant. Supportive care includes infection prevention, iron chelation where appropriate and management of transfusion needs.
Guidelines referenced:
WHO Classification of Haematopoietic and Lymphoid TumoursRevised International Prognostic Scoring System (IPSS-R)NCCN Guidelines — Myelodysplastic SyndromesContent on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.